ArticleEuropean journal of nuclear medicine and molecular imaging2021
Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Repeatability of tumour perfusion measurement with [EJNMMI research · 2026Article
- Rubidium ions as a novel therapeutic approach for glioblastoma.Scientific reports · 2025Article
- The impact of long axial field of view (LAFOV) PET on oncologic imaging.European journal of radiology · 2025Review
- Whole-body parametric mapping of tumour perfusion in metastatic prostate cancer using long axial field-of-view [European journal of nuclear medicine and molecular imaging · 2024Article
- Disrupting NaCancer & metabolism · 2024Article
- Extracardiac findings with increased perfusion during clinical O-15-HJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Recent Advances in Cardiovascular Diseases Research Using Animal Models and PET Radioisotope Tracers.International journal of molecular sciences · 2022Review
- Non-invasive radionuclide imaging of trace metal trafficking in health and disease: "PET metallomics".RSC chemical biology · 2022Review
- DCE-MRI of Brain Fluid Barriers:Tissue barriers · 2022Article
- Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness.EJNMMI research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 (
methodsOne hundred and two patients were included for pelvic
resultsTBF was the superior predictor (rho = 0.68, p < 0.0001, inflammatory lesions excluded) of MRI-guided biopsy grade group (GG) over lowest apparent diffusion coefficient (ADC) value (rho = -0.23, p = 0.01), independent of ADC value and tumour volume (p < 0.0001). PET could separate GG-2-5 from GG-1 and benign lesions with an area under the curve (AUC), sensitivity, and specificity of 0.79, 96%, and 59%, respectively. For separating GG-3-5 from GG-1-2 and benign lesions the AUC, sensitivity, and specificity were 0.82, 95%, and 63%, respectively. Na
conclusionTBF is an independent predictor of PCa aggressiveness and deserves more attention, as it may be valuable in separating clinically significant from insignificant PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.